Nothing Special   »   [go: up one dir, main page]

WO2004010974A3 - Gelatin capsule exhibiting reduced cross-linking - Google Patents

Gelatin capsule exhibiting reduced cross-linking Download PDF

Info

Publication number
WO2004010974A3
WO2004010974A3 PCT/US2003/024045 US0324045W WO2004010974A3 WO 2004010974 A3 WO2004010974 A3 WO 2004010974A3 US 0324045 W US0324045 W US 0324045W WO 2004010974 A3 WO2004010974 A3 WO 2004010974A3
Authority
WO
WIPO (PCT)
Prior art keywords
linking
reduced cross
exhibiting reduced
gelatin capsule
capsule exhibiting
Prior art date
Application number
PCT/US2003/024045
Other languages
French (fr)
Other versions
WO2004010974A2 (en
Inventor
Ping Gao
Original Assignee
Pharmacia Corp
Ping Gao
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp, Ping Gao filed Critical Pharmacia Corp
Priority to JP2004524263A priority Critical patent/JP2005538102A/en
Priority to AU2003257103A priority patent/AU2003257103A1/en
Priority to EP03772161A priority patent/EP1526846A2/en
Priority to MXPA05001167A priority patent/MXPA05001167A/en
Priority to CA002493980A priority patent/CA2493980A1/en
Priority to BR0313150-5A priority patent/BR0313150A/en
Publication of WO2004010974A2 publication Critical patent/WO2004010974A2/en
Publication of WO2004010974A3 publication Critical patent/WO2004010974A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)

Abstract

The present invention relates to compositions suitable for use in preparing gelatin capsules, to gelatin capsules exhibiting reduced cross-linking, and to methods of preparing such gelatin capsules.
PCT/US2003/024045 2002-07-31 2003-07-31 Gelatin capsule exhibiting reduced cross-linking WO2004010974A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2004524263A JP2005538102A (en) 2002-07-31 2003-07-31 Gelatin capsule showing reduced cross-linking
AU2003257103A AU2003257103A1 (en) 2002-07-31 2003-07-31 Gelatin capsule exhibiting reduced cross-linking
EP03772161A EP1526846A2 (en) 2002-07-31 2003-07-31 Gelatin capsule exhibiting reduced cross-linking
MXPA05001167A MXPA05001167A (en) 2002-07-31 2003-07-31 Gelatin capsule exhibiting reduced cross-linking.
CA002493980A CA2493980A1 (en) 2002-07-31 2003-07-31 Gelatin capsule exhibiting reduced cross-linking
BR0313150-5A BR0313150A (en) 2002-07-31 2003-07-31 Gelatin capsules exhibiting reduced cross-linking

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US39986202P 2002-07-31 2002-07-31
US39977602P 2002-07-31 2002-07-31
US39986302P 2002-07-31 2002-07-31
US39980802P 2002-07-31 2002-07-31
US60/399,808 2002-07-31
US60/399,776 2002-07-31
US60/399,863 2002-07-31
US60/399,862 2002-07-31

Publications (2)

Publication Number Publication Date
WO2004010974A2 WO2004010974A2 (en) 2004-02-05
WO2004010974A3 true WO2004010974A3 (en) 2004-08-05

Family

ID=31192378

Family Applications (4)

Application Number Title Priority Date Filing Date
PCT/US2003/024044 WO2004022032A2 (en) 2002-07-31 2003-07-31 Pharmaceutical dosage form comprising a sulfite compound
PCT/US2003/024043 WO2004010973A2 (en) 2002-07-31 2003-07-31 Pharmaceutical dosage form capable of maintaining stable dissolution profile upon storage
PCT/US2003/024042 WO2004010972A2 (en) 2002-07-31 2003-07-31 Pellicle-resistant gelatin capsule
PCT/US2003/024045 WO2004010974A2 (en) 2002-07-31 2003-07-31 Gelatin capsule exhibiting reduced cross-linking

Family Applications Before (3)

Application Number Title Priority Date Filing Date
PCT/US2003/024044 WO2004022032A2 (en) 2002-07-31 2003-07-31 Pharmaceutical dosage form comprising a sulfite compound
PCT/US2003/024043 WO2004010973A2 (en) 2002-07-31 2003-07-31 Pharmaceutical dosage form capable of maintaining stable dissolution profile upon storage
PCT/US2003/024042 WO2004010972A2 (en) 2002-07-31 2003-07-31 Pellicle-resistant gelatin capsule

Country Status (7)

Country Link
EP (4) EP1526845A2 (en)
JP (4) JP2005538102A (en)
AU (4) AU2003257103A1 (en)
BR (4) BR0313064A (en)
CA (4) CA2494069A1 (en)
MX (4) MXPA05001166A (en)
WO (4) WO2004022032A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8895059B2 (en) 2002-06-05 2014-11-25 Ivax Pharmaceuticals S.R.O. Reduction of cross-linking gelatin in gelatin capsules
KR101364762B1 (en) 2005-02-17 2014-02-17 신타 파마슈티칼스 코프. Compounds for the treatment of proliferative disorders
US7485323B2 (en) 2005-05-31 2009-02-03 Gelita Ag Process for making a low molecular weight gelatine hydrolysate and gelatine hydrolysate compositions
RU2406482C2 (en) * 2005-07-26 2010-12-20 Никокс С.А. Pharmaceutical composition of nitroxy derivative nonsteroid anti-inflammatory drugs
JP5503939B2 (en) * 2009-10-16 2014-05-28 東洋カプセル株式会社 Azelastine hydrochloride-containing capsule
JP6887456B2 (en) 2018-07-04 2021-06-16 キャプシュゲル・ベルジウム・エヌ・ヴィ A film-forming composition containing a surfactant or a surfactant and a salt as a whitening agent.
US11364478B2 (en) * 2019-05-22 2022-06-21 Mezzimatic, LLC Method of manufacturing throwable paintballs and paintballs made therefrom
PE20240222A1 (en) * 2020-12-01 2024-02-16 Lg Chemical Ltd COMPOUND FORMULATION FOR ORAL ADMINISTRATION COMPRISING 1-(3-CYANO-1-ISOPROPYL-INDOL-5-IL)PYRAZOLE-4-CARBOXYLIC ACID AND A PROCESS FOR ITS PREPARATION
CN113230241A (en) * 2021-06-11 2021-08-10 北京畅盛医药科技有限公司 Application of tris (hydroxymethyl) aminomethane salt in medicine for treating cardiovascular and cerebrovascular diseases

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2204401A1 (en) * 1972-11-01 1974-05-24 Meiji Seika Co
GB2073589A (en) * 1980-04-14 1981-10-21 Squibb & Sons Inc Diagnostic and therapeutic radio pharmaceutical capsules
FR2617047A1 (en) * 1987-06-23 1988-12-30 Sanofi Sa Gelatin composition which withstands tanning, capsules based on this composition and their pharmaceutical application, in particular to fenofibrate
EP0695544A1 (en) * 1994-08-05 1996-02-07 Shionogi & Co., Ltd. Hard gelatin capsules resistant to denaturation and the production thereof
WO1996014365A2 (en) * 1994-11-07 1996-05-17 Warner-Lambert Company Process for stabilizing gelatin products

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4590183A (en) * 1985-04-22 1986-05-20 Sterling Drug Inc. Gastric cytoprotection with sodium thiosulfate in oral administration of aspirin
JP2790659B2 (en) * 1989-06-30 1998-08-27 帝国臓器製薬株式会社 Gelatin capsule
NO950970L (en) * 1994-03-15 1995-09-18 Senju Pharma Co Method of Stabilizing Pranoprofen and Stable Liquid Preparations of Pranoprofen
IT1269583B (en) * 1994-04-26 1997-04-08 Bayer Italia Spa PHARMACEUTICAL PREPARATIONS BASED ON A SOLUTION OF KETOPROFENE IN SOFT GELATINE CAPSULES AND METHOD FOR THEIR PRODUCTION
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2204401A1 (en) * 1972-11-01 1974-05-24 Meiji Seika Co
GB2073589A (en) * 1980-04-14 1981-10-21 Squibb & Sons Inc Diagnostic and therapeutic radio pharmaceutical capsules
FR2617047A1 (en) * 1987-06-23 1988-12-30 Sanofi Sa Gelatin composition which withstands tanning, capsules based on this composition and their pharmaceutical application, in particular to fenofibrate
EP0695544A1 (en) * 1994-08-05 1996-02-07 Shionogi & Co., Ltd. Hard gelatin capsules resistant to denaturation and the production thereof
WO1996014365A2 (en) * 1994-11-07 1996-05-17 Warner-Lambert Company Process for stabilizing gelatin products

Also Published As

Publication number Publication date
AU2003257982A8 (en) 2004-02-16
MXPA05000862A (en) 2005-04-19
MXPA05001167A (en) 2005-05-16
EP1526846A2 (en) 2005-05-04
JP2005538102A (en) 2005-12-15
BR0313150A (en) 2005-06-28
WO2004010972A2 (en) 2004-02-05
WO2004022032A2 (en) 2004-03-18
CA2493974A1 (en) 2004-03-18
WO2004010972A3 (en) 2004-07-29
WO2004022032A3 (en) 2004-08-12
AU2003257103A8 (en) 2004-02-16
JP2006500389A (en) 2006-01-05
AU2003257102A1 (en) 2004-03-29
AU2003257981A8 (en) 2004-02-16
EP1526845A2 (en) 2005-05-04
JP2005538993A (en) 2005-12-22
MXPA05001272A (en) 2005-04-28
AU2003257103A1 (en) 2004-02-16
JP2005538994A (en) 2005-12-22
AU2003257982A1 (en) 2004-02-16
EP1526847A2 (en) 2005-05-04
AU2003257981A1 (en) 2004-02-16
CA2493980A1 (en) 2004-02-05
CA2494069A1 (en) 2004-02-05
WO2004010974A2 (en) 2004-02-05
WO2004010973A3 (en) 2004-08-05
AU2003257102A8 (en) 2004-03-29
MXPA05001166A (en) 2005-05-16
BR0313064A (en) 2005-06-28
WO2004010973A2 (en) 2004-02-05
BR0313149A (en) 2005-06-28
CA2494358A1 (en) 2004-02-05
BR0312875A (en) 2005-06-28
EP1526844A2 (en) 2005-05-04

Similar Documents

Publication Publication Date Title
IL165977A (en) Substituted pyrimidinylaminobenzamides , process for the preparation thereof and pharmaceutical compositions comprising the same
WO2005034650A8 (en) Weight-loss supplement
WO2003103582A3 (en) Reduction of gelatin cross-linking
AP2006003508A0 (en) Method for the preparation of group IB-IIIa_VIA quaternary or higher alloy semiconductor films.
EP1557438A4 (en) Capsule type hardener and composition
WO2005011592A3 (en) Substituted indazole-o-glucosides
WO2005012243A3 (en) Substituted indole-o-glucosides
AU2003239609A1 (en) 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same
AR033711A1 (en) PHARMACEUTICAL COMPOSITIONS
AP2004003154A0 (en) Novel perindopril salt and pharmaceutical compositions containing same.
WO2005012356A3 (en) Gelatin capsules
TW200508197A (en) Indolone-acetamide derivatives, processes for preparing them and their uses
AU2003297199A1 (en) Human chondroitinase glycoprotein (chasegp), process for preparing the same, and pharmaceutical compositions comprising thereof
IL209789A0 (en) Metabolites of 3-(2-dimethylaminomethyl-cyclohexyl)- phenol, pharmaceutical compositions comprising the same and uses thereof
PL1670769T3 (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
IL161428A0 (en) Oligoamine derivatives, methods for the production thereof and pharmaceutical compositions containing the same
WO2004010974A3 (en) Gelatin capsule exhibiting reduced cross-linking
ZA200309514B (en) Pyrido-pyrido-pyrrolo pyrrolo-indole and pyrido-pyrrolo pyrrolo carbazole derivatives, method for the production thereof and pharmaceutical compositions containing said derivatives.
AU2003251695A1 (en) Novel thiophene derivatives, preparation method thereof and pharmaceutical compositions containing same
EP1499593A4 (en) Quinoline derivatives as caspase-3 inhibitor, preparation for producing the same and pharmaceutical composition comprising the same
AU2003218824A8 (en) Benzopyran derivatives substituted with secondary amines including tetrazole, method for the preparation thereof and pharmaceutical compositions containing them
IL162524A0 (en) Derivatives of (pyridin-3-yl)-1-azabicycloÄ3.2.1Ü octane, their preparation and their terapeutic application
EP1515960A4 (en) 2-thioxothiazole derivative, method for preparing the same, and pharmaceutical composition containing the same
WO2000041472A3 (en) Binding partners for 5-ht5-receptors for the treatment of migraine
AU2002243097A1 (en) Quinoline derivatives, their preparation and pharmaceutical compositions comprising the same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2493980

Country of ref document: CA

Ref document number: 2003772161

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/001167

Country of ref document: MX

Ref document number: 2004524263

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2003772161

Country of ref document: EP